A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

<strong>Background:</strong> Focal adhesion kinase (FAK) is important in cancer growth, survival, invasion, and migration. The purpose of this study was to determine the maximum tolerated dose (MTD), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the FAK inhibitor, GSK225609...

Full description

Bibliographic Details
Main Authors:	Soria, J, Gan, H, Blagden, S, Plummer, R, Arkenau, H, Ranson, M, Evans, T, Zalcman, G, Bahleda, R, Hollebecque, A, Lemech, C, Dean, E, Brown, J, Gibson, D, Peddareddigari, V, Murray, S, Nebot, N, Mazumdar, J, Swartz, L, Auger, K, Fleming, R, Singh, R, Millward, M
Format:	Journal article
Published:	Oxford University Press 2016

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Similar Items